Glaucoma Medications Market
Glaucoma Medications Market Global Industry Assessment & Forecast
#
Pages:
142
2021
Nov - 2021
VMR-2021-0522
Segments Covered
By
Indication Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others
-
By
Drug Class Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others
Snapshot
 Forecast
Years:
|
2021 - 2028 |
 Historical
Years:
|
2016 - 2020 |
 Revenue
2021: |
7.51 Billion |
 Revenue 2028:
|
10.76 Billion |
 Revenue CAGR
(2021 - 2028): |
4.6 |
Fastest Growing Region (2022 -
2028)
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
FAQ
Frequently Asked Question
What is the global demand for Glaucoma Medications in terms of revenue?
-
The global Glaucoma Medications valued at 7.51 Billion in 2020 and is expected to reach 10.76 Billion in 2028 growing at a CAGR of 4.6%.
Which are the prominent players in the market?
-
The prominent players in the market are Laboratoires Thea, Actavis, APOTEX, GE Medical, Mylan, Taj Pharmaceuticals, Teva Pharmaceutical, Jamp Pharma, Greenstone, Mint Pharmaceuticals, SANDOZ, Bausch + Lomb, Fresenius, Sun Pharma, Laboratoire Riva, Pfizer, Novartis..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 4.6% between 2021 and 2028.
What are the driving factors fueling the growth of the market?
-
The driving factors of the Glaucoma Medications include
- The rising cases of glaucoma across the globe and new drug developments are expected to fuel the growth of the market during the forecast period.
- The technological advancement in treatment of glaucoma, and various pharmaceutical and biotechnological companies are investing in new product development for glaucoma is a factor driving the market.
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Glaucoma Medications in 2020.
